Westfield Capital Management
TEVA icon

Westfield Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Westfield Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,946,519
Closed -$148M – 274
2016
Q2 		$148M Buy
2,946,519
+285,978
+11% +$15.2M 1.22% 15
2016
Q1 		$142M Sell
2,660,541
-1,280,909
-32% -$75.2M 1.08% 24
2015
Q4 		$259M Sell
3,941,450
-1,613,980
-29% -$99.7M 1.74% 4
2015
Q3 		$314M Sell
5,555,430
-302,161
-5% -$19.6M 2.22% 3
2015
Q2 		$346M Buy
5,857,591
+266,720
+5% +$16.5M 2.11% 3
2015
Q1 		$348M Buy
5,590,871
+932,152
+20% +$54.2M 2.01% 5
2014
Q4 		$268M Sell
4,658,719
-28,806
-0.6% -$1.6M 1.58% 7
2014
Q3 		$252M Sell
4,687,525
-481,029
-9% -$25.5M 1.54% 6
2014
Q2 		$271M Buy
5,168,554
+256,191
+5% +$13.1M 1.61% 6
2014
Q1 		$260M Sell
4,912,363
-261,676
-5% -$12.1M 1.55% 5
2013
Q4 		$207M Buy
+5,174,039
New +$204M 1.22% 8

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management's TEVA Position: Q3 2016 in Review

Westfield Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 2,946,519 shares — an estimated $148M sold.

Westfield Capital Management first reported a position in TEVA in Q4 2013 and held it in 11 quarters. The position peaked at $348M in Q1 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Westfield Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Westfield Capital Management sold 2,946,519 Teva Pharmaceuticals shares in Q3 2016, an estimated $148M.
  • Westfield Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 11 quarters.
  • Westfield Capital Management's Teva Pharmaceuticals position peaked at $348M in Q1 2015.
  • 795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Westfield Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.